pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Hepatocellular Carcinoma
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) has one of the worst prognoses for survival as it is poorly responsive to both conventional chemotherapy and mechanism-directed therapy. This results from a lack of therapeutic concentration in the tumor tissue coupled with the highly toxic off-site effects exhibited by these compounds. Consequently, we believe the best packaging for holistic therapy for HCC will involve three components: a potent therapeutic, a rationally designed drug delivery vehicle to enrich the target site concentration of the drug, and a surface ligand that can enable a greater propensity to internalization by tumor cells compared to the parenchyma. We screened a library containing hundreds of compounds against a panel of HCC cells and found the natural product, triptolide, to be more effective than sorafenib, doxorubicin, and daunorubicin, which are the current standards of therapy. However, the potential clinical application of triptolide is limited due to its poor solubility and high toxicity. Consequently, we synthesized tumor pH-sensitive nanoformulated triptolide coated with folate for use in an HCC-subpopulation that overexpresses the folate receptor. Our results show triptolide itself can prevent disease progression, but at the cost of significant toxicity. Conversely, our pH-sensitive nanoformulated triptolide facilitates uptake into the tumor, and specifically tumor cells, leading to a further increase in efficacy while mitigating systemic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Polymeric nanomedicine for cancer therapy
Park, J. H., Lee, S., Kim, J.-H., Park, K., Kim, K., & Kwon, I. C. (2008) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.09.003 · Cited by 506
Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Bard-Chapeau, E. A., Li, S., Ding, J., Zhang, S. S., Zhu, H. H., Princen, F., Fang, D. D., Han, T., Bailly-Maitre, B., Poli, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.023 · Cited by 332
Cited by
Prospects of Nanoscience with Nanocrystals
Kovalenko, M. V., Manna, L., Cabot, A., Hens, Z., Talapin, D. V., Kagan, C. R., Klimov, V. I., Rogach, A. L., Reiss, P., Milliron, D. J., et al. (2015) · ACS Nano · doi:10.1021/nn506223h · Cited by 1,226
Self-citationEnhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Tang, L., Zheng, Y., Melo, M. B., Mabardi, L., Castaño, A. P., Xie, Y.-Q., Li, N., Kudchodkar, S. B., Wong, H. C., Jeng, E. K., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4181 · Cited by 660
Preparation and application of pH-responsive drug delivery systems
Ding, H., Tan, P., Fu, S., Tian, X., Zhang, H., Ma, X., Gu, Z., & Luo, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.056 · Cited by 645
Synthesis of Semiconductor Nanocrystals, Focusing on Nontoxic and Earth-Abundant Materials
Reiss, P., Carrière, M., Lincheneau, C., Vaure, L., & Tamang, S. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00116 · Cited by 635
Chemical Synthesis and Assembly of Uniformly Sized Iron Oxide Nanoparticles for Medical Applications
Ling, D., Lee, N., & Hyeon, T. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00038 · Cited by 513
Self-citationZhu, Y., Ouyang, Z., Du, H., Wang, M., Wang, J., Sun, H., Kong, L., Xu, Q., Ma, H., & Sun, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.022 · Cited by 414
Device-assisted transdermal drug delivery
Lee, H., Song, C., Baik, S., Kim, D., Hyeon, T., & Kim, D.-H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.009 · Cited by 343
Self-citationChen, S.-R., Dai, Y., Zhao, J., Lin, L., Wang, Y., & Wang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00104 · Cited by 326
The structural modification of natural products for novel drug discovery
Yao, H., Liu, J., Xu, S., Zhu, Z., & Xu, J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1272757 · Cited by 275
Triptolide delivery: Nanotechnology-based carrier systems to enhance efficacy and limit toxicity
Ren, Q., Li, M., Deng, Y., Lu, A., & Lu, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105377 · Cited by 64
Lv, Y., Liu, P., Ding, H., Wu, Y., Yan, Y., Liu, H., Wang, X., Huang, F., Zhao, Y., & Tian, Z. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b05150 · Cited by 56
Zhu, C., Zhang, H., Li, W., Luo, L., Guo, X., Wang, Z., Kong, F., Li, Q., Yang, J., Du, Y., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.043 · Cited by 53
Metadata
- Authors
- Ling, D., Xia, H., Park, W., Hackett, M. J., Song, C., Na, K., Hui, K. M., & Hyeon, T.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-08-05
- Volume
- 8
- Issue
- 8
- Pages
- 8027-8039
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2314552137
- Cited by
- 135
- References
- 7
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.